The GNB2 antibody targets the beta-2 subunit of heterotrimeric G proteins, which are critical components of intracellular signaling pathways. GNB2 encodes the β2 subunit, one of five β-subunit isoforms (β1–β5) that form stable dimers with γ-subunits to regulate G protein-coupled receptor (GPCR) signaling. These β/γ complexes modulate downstream effectors such as adenylyl cyclase, phospholipase C, and ion channels, influencing cellular processes like neurotransmission, hormone secretion, and cell proliferation.
GNB2 antibodies are widely used as research tools to study the expression, localization, and function of the β2 subunit in various tissues and disease models. They are essential for techniques like Western blotting, immunohistochemistry, and immunofluorescence to visualize protein levels or track dynamic interactions in signaling cascades. Dysregulation of GNB2 has been implicated in neurodevelopmental disorders, cardiovascular diseases, and cancer, where aberrant GPCR signaling may drive pathogenesis. For example, altered GNB2 expression has been linked to tumor progression and resistance to therapies targeting signaling pathways.
Validated GNB2 antibodies typically recognize conserved epitopes across species, enabling cross-disciplinary studies in model organisms. Researchers also use these antibodies to explore post-translational modifications or mutations affecting β2-subunit stability and function. Understanding GNB2's role through antibody-based assays contributes to elucidating disease mechanisms and identifying potential therapeutic targets in GPCR-related pathologies.